ABO Compatibility Chart
Transfusion medicine
ABO/Rh Compatibility
The presence or absence of A and/or B antigens and antibodies, as outlined in the table below, is the basis for determining ABO type compatibility between patient and donor. ABO antibodies develop naturally starting at approximately 3 months of age, whereas antibodies against Rh occur in Rh negative individuals only after exposure to Rh positive red cells via transfusion or pregnancy. When assessing the compatibility of blood and components, both patient and donor antigens and antibodies must be considered.
ABO Antigens/Antibodies Chart
Description | Indication |
Leukoreduction: Removal of white cells either through filtration or special collection techniques NOTE: Leukoreduction is not indicated in components that contain no viable white cells (Plasma and Cryoprecipitate). |
|
CMV Seronegative: RBCs and Platelets from a Cytomegalovirus (CMV) seronegative donor. Blood products are considered “CMV safe” if either CMV sero-negative or leukocyte reduced. |
|
Irradiation: Inactivation of lymphocytes to prevent Transfusion-related Graft Versus Host Disease (TA-GVHD), a very rare, but fatal (90-100%) complication of blood transfusion. NOTE: Irradiation is not indicated in components that contain no viable white cells (Plasma and Cryoprecipitate). |
|
Washed Red Blood Cells and Platelets: Washing with saline to remove donor plasma. This requires BloodworksNW physician approval. CAUTIONARY NOTE: For red cells, approximately 20% of the cells are lost. For platelets, both platelet recovery and function are severely impaired. |
|
Volume Reduced Platelets: Removal of donor plasma. CAUTIONARY NOTE: Approximately 10% of platelets are lost, platelets are activated and function is lost. |
|